302 results on '"Fell, Geoffrey"'
Search Results
2. Clinical trial links oncolytic immunoactivation to survival in glioblastoma
3. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
4. Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia
5. Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study
6. Patient perspectives on testing for clonal hematopoiesis of indeterminate potential
7. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
8. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
9. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects
10. Autopsy findings from patients diagnosed with COVID-19 demonstrate unique morphological patterns in bone marrow and lymph node.
11. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
12. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
13. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide
14. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia
15. Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers
16. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
17. Choosing Wisely between Radiotherapy Dose-Fractionation Schedules: The Molecular Graded Prognostic Assessment for Elderly Glioblastoma Patients
18. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
19. CTNI-80. INTUITT-NF2, AN ADAPTIVE PLATFORM-BASKET TRIAL FOR NF2-RELATED SCHWANNOMATOSIS PATIENTS WITH PROGRESSIVE SCHWANNOMAS, MENINGIOMAS, AND EPENDYMOMAS: PRIMARY OUTCOME OF THE BRIGATINIB TREATMENT ARM
20. CTNI-17. APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIES
21. Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
22. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
23. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas
24. MDS-556 Comparison of Demographics, Disease Characteristics and Outcomes Between Black and White Patients With Myelodysplastic Syndrome: A Population-Based Study
25. Correcting the record on anemia of aging: a statistical reanalysis
26. Supplemental Fig. S2 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
27. Supplemental Table S6 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
28. Autopsy findings from patients diagnosed with COVID-19 demonstrate unique morphological patterns in bone marrow and lymph node
29. Data from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
30. Clonal Hematopoiesis in Young Women Treated for Breast Cancer
31. Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
32. Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
33. Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
34. Table S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
35. Supplementary Data from Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
36. Supplementary Data from Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications
37. Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
38. In VivoModeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
39. Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study
40. FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3-wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study
41. Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults
42. Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome
43. A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
44. Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19
45. Poster: MDS-556 Comparison of Demographics, Disease Characteristics and Outcomes Between Black and White Patients With Myelodysplastic Syndrome: A Population-Based Study
46. Abstract A39: Targeting tumor-microenvironmental dependencies as a therapeutic approach in Chronic Lymphocytic Leukemia (CLL)
47. Peripheral blood CD3 + T‐cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies
48. Optimizing CpG spatial distribution with DNA origami for Th1-polarized therapeutic vaccination
49. Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.
50. Comparison of demographics, disease characteristics, and outcomes between African American patients and White patients with myelodysplastic syndrome: A population-based study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.